Back to Search Start Over

The Importance of Outcomes Ascertainment for Accurate Assessment of the Mammography Screening Cancer Detection Rate: A Simulation Study.

Authors :
Burnside ES
Lasarev MR
Sprague BL
Miglioretti DL
Alexandridis RA
Lee JM
Pisano ED
Smith RA
Source :
Journal of the American College of Radiology : JACR [J Am Coll Radiol] 2024 Mar; Vol. 21 (3), pp. 376-386. Date of Electronic Publication: 2023 Nov 03.
Publication Year :
2024

Abstract

Purpose: Cancer detection rate (CDR), an important metric in the mammography screening audit, is designed to ensure adequate sensitivity. Most practices use biopsy results as the reference standard; however, commonly ascertainment of biopsy results is incomplete. We used simulation to determine the relationship between the cancer ascertainment rate of biopsy (AR-biopsy), CDR estimation, and associated error rates in classifying whether practices and radiologists meet the established ACR benchmark of 2.5 per 1,000.<br />Materials and Methods: We simulated screening mammography volume, number of cancers detected, and CDR, using negative binomial and beta-binomial distributions, respectively. Simulations were performed at both the practice and radiologist level. Average CDR was based on linearly rescaling a published CDR by the AR-biopsy. CDR distributions were simulated for AR-biopsy between 5% and 100% in steps of five percentage points and were summarized with boxplots and smoothed histograms over the range of AR-biopsy, to quantify the proportion of practices and radiologists meeting the ACR benchmark at each level of AR-biopsy.<br />Results: Decreasing AR-biopsy led to an increasing probability of categorizing CDR performance as being below the ACR benchmark. Our simulation predicts that at the practice level, an AR-biopsy of 65% categorizes 17.6% below the benchmark (compared to 1.6% at an AR-biopsy of 100%), and at the radiologist level, an AR-biopsy of 65% categorizes 34.7% as being below the benchmark (compared to 11.6% at an AR-biopsy of 100%).<br />Conclusions: Our simulation demonstrates that decreasing the AR-biopsy (in currently clinically relevant ranges) has the potential to artifactually lower the assessed CDR on both the practice and radiologist levels and may, in turn, increase the chance of erroneous categorization of underperformance per the ACR benchmark.<br /> (Copyright © 2023 American College of Radiology. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1558-349X
Volume :
21
Issue :
3
Database :
MEDLINE
Journal :
Journal of the American College of Radiology : JACR
Publication Type :
Academic Journal
Accession number :
37922974
Full Text :
https://doi.org/10.1016/j.jacr.2023.09.014